PwC’s Corporate Finance team is pleased to announce the sale of a majority in FOSTAG Formenbau AG (“FOSTAG”), a leading manufacturer of high-performance injection moulds, to a group of Swiss private investors led by BLR Partners. PwC acted as exclusive financial advisor to the shareholders of FOSTAG in connection with the transaction.
Since 1955, FOSTAG Formenbau AG has been one of the world's leading manufacturers of high-performance injection moulds for applications in medical technology as well as for thin-walled packaging and closures. The medical technology sector in particular has developed very positively in recent years. In order to continue the long-term growth, the two owners Markus and Rolf Mühlemann have decided to sell the majority of shares to a group of Swiss private investors. The group of investors around BLR Partners has proven entrepreneurial experience as well as industrial know-how and will be represented on the Board of Directors by Bernhard Merki (new Chairman), Patrick Schwyter and Ueli Looser. The two owners will retain a significant stake in the company and will continue to manage the operational activities. Thus, Markus Mühlemann as CEO and Rolf Mühlemann as COO will also in future be responsible for the further development of FOSTAG. This long-term partnership supports the next growth phase and ensures continuity for the employees, customers, partners, suppliers and also for the location in Stein am Rhein.
The transaction has been signed and closed on April 20, 2021.
Partner, Corporate Finance / M&A Leader, PwC Switzerland
Tel: +41 58 792 15 39
Director, Corporate Finance / M&A, PwC Switzerland
Tel: +41 58 792 1542
Corporate Finance / M&A, PwC Switzerland
Tel: +41 58 792 4928
Assistant Manager, Corporate Finance / M&A, PwC Switzerland
Tel: +41 58 792 15 97